Entellus Medical, Inc. (ENTL) Reaches $23.84 52-Week High; Celadon Group (CGI) SI Decreased By 12.25%

December 7, 2017 - By Kurt Siggers

Celadon Group Incorporated (NYSE:CGI) had a decrease of 12.25% in short interest. CGI’s SI was 3.58M shares in December as released by FINRA. Its down 12.25% from 4.08 million shares previously. With 433,100 avg volume, 8 days are for Celadon Group Incorporated (NYSE:CGI)’s short sellers to cover CGI’s short positions. The SI to Celadon Group Incorporated’s float is 13.37%. The stock increased 0.38% or $0.025 during the last trading session, reaching $6.625. About 45,898 shares traded. Celadon Group, Inc. (NYSE:CGI) has declined 74.33% since December 7, 2016 and is downtrending. It has underperformed by 91.03% the S&P500.

The stock of Entellus Medical, Inc. (NASDAQ:ENTL) hit a new 52-week high and has $25.27 target or 6.00% above today’s $23.84 share price. The 6 months bullish chart indicates low risk for the $607.18 million company. The 1-year high was reported on Dec, 7 by Barchart.com. If the $25.27 price target is reached, the company will be worth $36.43 million more. The stock increased 48.88% or $7.825 during the last trading session, reaching $23.835. About 4.14M shares traded or 3040.02% up from the average. Entellus Medical, Inc. (NASDAQ:ENTL) has declined 17.59% since December 7, 2016 and is downtrending. It has underperformed by 34.29% the S&P500.

Celadon Group, Inc., through its subsidiaries, provides transportation services between the United States, Canada, and Mexico. The company has market cap of $183.65 million. It operates through three divisions: Asset-Based, Asset-Light, and Equipment Leasing and Services. It has a 77.03 P/E ratio. The Asset-Based segment offers dry van, refrigerated, and flatbed services; cross-border services between the United States and each of Mexico and Canada; intra-Mexico and intra-Canada services; contract services; regional and specialized short haul services; and rail intermodal services.

Investors sentiment decreased to 0.54 in Q2 2017. Its down 1.59, from 2.13 in 2017Q1. It dived, as 56 investors sold Celadon Group, Inc. shares while 25 reduced holdings. 25 funds opened positions while 19 raised stakes. 22.81 million shares or 22.97% less from 29.61 million shares in 2017Q1 were reported. Lpl Finance Ltd Liability Co invested in 23,902 shares or 0% of the stock. Paloma reported 98,628 shares. D E Shaw And reported 0% of its portfolio in Celadon Group, Inc. (NYSE:CGI). Bnp Paribas Arbitrage Sa accumulated 406 shares. Tfs Limited Liability Corporation has 30,245 shares. Luminus Mgmt Limited Liability Com invested 0.08% in Celadon Group, Inc. (NYSE:CGI). Phoenix Inv Adviser Limited Liability Co invested in 0.55% or 255,276 shares. Redmond Asset Mgmt Ltd Limited Liability Company reported 59,757 shares or 0.09% of all its holdings. Fmr Limited Liability Com invested 0% in Celadon Group, Inc. (NYSE:CGI). First Trust Ltd Partnership stated it has 0% in Celadon Group, Inc. (NYSE:CGI). Lmr Ptnrs Ltd Liability Partnership accumulated 0.01% or 68,498 shares. Invesco invested in 103,869 shares. Moreover, Quantbot Techs Ltd Partnership has 0% invested in Celadon Group, Inc. (NYSE:CGI). 897,360 are owned by Foundry Prns Lc. Northern Tru holds 295,431 shares.

Among 8 analysts covering Celadon Group (NYSE:CGI), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Celadon Group had 19 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of Celadon Group, Inc. (NYSE:CGI) earned “Outperform” rating by Credit Suisse on Monday, May 15. The stock of Celadon Group, Inc. (NYSE:CGI) earned “Hold” rating by Stifel Nicolaus on Friday, February 10. The rating was downgraded by Stifel Nicolaus to “Hold” on Friday, June 24. The stock has “Overweight” rating by KeyBanc Capital Markets on Tuesday, January 12. The firm earned “Buy” rating on Friday, April 7 by Aegis Capital. The stock of Celadon Group, Inc. (NYSE:CGI) earned “Hold” rating by Stifel Nicolaus on Friday, December 16. Cowen & Co maintained Celadon Group, Inc. (NYSE:CGI) rating on Friday, July 31. Cowen & Co has “Outperform” rating and $30 target. The company was maintained on Friday, April 29 by Cowen & Co. The rating was downgraded by Avondale on Friday, November 4 to “Mkt Perform”. Cowen & Co maintained the shares of CGI in report on Friday, October 30 with “Outperform” rating.

Entellus Medical, Inc., a medical technology company, focuses on the design, development, and commercialization of products for the minimally invasive treatment of patients suffering from chronic and recurrent sinusitis. The company has market cap of $607.18 million. The firm offers XprESS Multi-Sinus Dilation family of products consisting of XprESS Pro device, XprESS LoProfile device, and XprESS Ultra device, which open an obstructed or narrowed drainage pathway of a sinus cavity by means of trans-nasal balloon sinus dilation. It currently has negative earnings. It also provides PathAssist tools, such as LED Light Fiber, a single-use tool that provides real-time high intensity red trans-illumination of the sinus cavity with its battery power; Light Fiber, a single-use tool that provides real-time trans-illumination of the sinus cavity; Light Seeker, a tool with optical fibers embedded into the device to allow ear, nose, and throat physicians to access the frontal sinus and trans-illuminate the sinus cavity; Maxillary Seeker, a tool that allow users to find the correct angle to access the natural maxillary ostia; and Sphenoid Seeker/Freer, a two-in-one tool that enables ENT physicians to navigate access to the sphenoid ostium.

Analysts await Entellus Medical, Inc. (NASDAQ:ENTL) to report earnings on February, 20. They expect $-0.38 EPS, up 2.56% or $0.01 from last year’s $-0.39 per share. After $-0.49 actual EPS reported by Entellus Medical, Inc. for the previous quarter, Wall Street now forecasts -22.45% EPS growth.

Among 5 analysts covering Entellus Medical (NASDAQ:ENTL), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Entellus Medical has $27 highest and $17.0 lowest target. $21.25’s average target is -10.85% below currents $23.835 stock price. Entellus Medical had 8 analyst reports since August 9, 2015 according to SRatingsIntel. The stock has “Buy” rating by Deutsche Bank on Thursday, October 6. Piper Jaffray maintained the stock with “Buy” rating in Monday, August 21 report. BTIG Research initiated the shares of ENTL in report on Tuesday, June 14 with “Buy” rating. Canaccord Genuity maintained Entellus Medical, Inc. (NASDAQ:ENTL) rating on Sunday, August 9. Canaccord Genuity has “Buy” rating and $27 target. The rating was maintained by Canaccord Genuity on Monday, October 16 with “Hold”. The firm has “” rating given on Tuesday, September 29 by Piper Jaffray.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.